Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Zanzalintinib + Pembrolizumab in Resectable Clear Cell Renal Cell Carcinoma
KCT0012141Phase 2Not yet recruiting
- Sponsor
- Samsung Bioepis
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib, pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Samsung Bioepis. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zanzalintinibpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on KCT0012141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012141.